You just read:

Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder

News provided by

Alkermes plc

Jan 28, 2020, 07:00 ET